136 related articles for article (PubMed ID: 9276154)
1. Potent, long-acting bradykinin antagonists for a wide range of applications.
Stewart JM; Gera L; Chan DC; Whalley ET; Hanson WL; Zuzack JS
Can J Physiol Pharmacol; 1997 Jun; 75(6):719-24. PubMed ID: 9276154
[TBL] [Abstract][Full Text] [Related]
2. Potent, long-acting, orally-active bradykinin antagonists for a wide range of applications.
Stewart JM; Gera L; Chan DC; Whalley ET; Hanson WL; Zuzack JS
Immunopharmacology; 1997 Jun; 36(2-3):167-72. PubMed ID: 9228542
[TBL] [Abstract][Full Text] [Related]
3. A new generation of bradykinin antagonists.
Stewart JM; Gera L; Hanson W; Zuzack JS; Burkard M; McCullough R; Whalley ET
Immunopharmacology; 1996 Jun; 33(1-3):51-60. PubMed ID: 8856115
[TBL] [Abstract][Full Text] [Related]
4. Bradykinin-related compounds as new drugs for cancer and inflammation.
Stewart JM; Gera L; Chan DC; Bunn PA; York EJ; Simkeviciene V; Helfrich B
Can J Physiol Pharmacol; 2002 Apr; 80(4):275-80. PubMed ID: 12025961
[TBL] [Abstract][Full Text] [Related]
5. MEN 11270, A novel selective constrained peptide antagonist with high affinity at the human B2 kinin receptor.
Meini S; Quartara L; Rizzi A; Patacchini R; Cucchi P; Giolitti A; Calò G; Regoli D; Criscuoli M; Maggi CA
J Pharmacol Exp Ther; 1999 Jun; 289(3):1250-6. PubMed ID: 10336513
[TBL] [Abstract][Full Text] [Related]
6. Correlation of secondary structures of bradykinin B1 receptor antagonists with their activity.
Miskolzie M; Gera L; Stewart JM; Kotovych G
J Biomol Struct Dyn; 2002 Feb; 19(4):585-93. PubMed ID: 11843620
[TBL] [Abstract][Full Text] [Related]
7. Inflammation modifies the role of cyclooxygenases in the contractile responses of the rat detrusor smooth muscle to kinin agonists.
Meini S; Lecci A; Cucchi P; Catalioto RM; Criscuoli M; Maggi CA
J Pharmacol Exp Ther; 1998 Oct; 287(1):137-43. PubMed ID: 9765332
[TBL] [Abstract][Full Text] [Related]
8. Bradykinin receptor antagonists containing N-substituted amino acids: in vitro and in vivo B(2) and B(1) receptor antagonist activity.
Goodfellow VS; Marathe MV; Kuhlman KG; Fitzpatrick TD; Cuadrado D; Hanson W; Zuzack JS; Ross SE; Wieczorek M; Burkard M; Whalley ET
J Med Chem; 1996 Mar; 39(7):1472-84. PubMed ID: 8691478
[TBL] [Abstract][Full Text] [Related]
9. Bradykinin receptor antagonists type 2 attenuate the inflammatory changes in peptidoglycan-induced acute arthritis in the Lewis rat.
Uknis AB; DeLa Cadena RA; Janardham R; Sartor RB; Whalley ET; Colman RW
Inflamm Res; 2001 Mar; 50(3):149-55. PubMed ID: 11339503
[TBL] [Abstract][Full Text] [Related]
10. Characterization of bradykinin receptors in a human osteoblastic cell line.
Brechter AB; Lerner UH
Regul Pept; 2002 Jan; 103(1):39-51. PubMed ID: 11738247
[TBL] [Abstract][Full Text] [Related]
11. In vivo pharmacological profile of novel, potent, stable BK antagonists at B1 and B2 receptors.
Hanson WL; McCullough RG; Selig WM; Wieczorek M; Ross S; Whalley ET; Stewart JM; Gera L
Immunopharmacology; 1996 Jun; 33(1-3):191-3. PubMed ID: 8856147
[No Abstract] [Full Text] [Related]
12. Comparative profile of novel potent bradykinin antagonists at human B1 and B2 receptors.
Burkard M; Zuzack JS; Jones S; Francis M; Whalley ET; Stewart JM; Gera L
Immunopharmacology; 1996 Jun; 33(1-3):186-90. PubMed ID: 8856146
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterization of canine bradykinin receptors in prostatic culture and in isolated prostate.
Srinivasan D; Burbach LR; Daniels DV; Ford AP; Bhattacharya A
Br J Pharmacol; 2004 May; 142(2):297-304. PubMed ID: 15155537
[TBL] [Abstract][Full Text] [Related]
14. A single position in the third transmembrane domains of the human B1 and B2 bradykinin receptors is adjacent to and discriminates between the C-terminal residues of subtype-selective ligands.
Fathy DB; Mathis SA; Leeb T; Leeb-Lundberg LM
J Biol Chem; 1998 May; 273(20):12210-8. PubMed ID: 9575169
[TBL] [Abstract][Full Text] [Related]
15. B-9972 (D-Arg-[Hyp3,Igl5,Oic7,Igl8]-bradykinin) is an inactivation-resistant agonist of the bradykinin B2 receptor derived from the peptide antagonist B-9430 (D-Arg-[Hyp3,Igl5,D-Igl7,Oic8]-bradykinin): pharmacologic profile and effective induction of receptor degradation.
Bawolak MT; Gera L; Morissette G; Stewart JM; Marceau F
J Pharmacol Exp Ther; 2007 Nov; 323(2):534-46. PubMed ID: 17699739
[TBL] [Abstract][Full Text] [Related]
16. A new class of pseudopeptide antagonists of the kinin B1 receptor containing alkyl spacers.
Galoppini C; Meini S; Tancredi M; Di Fenza A; Triolo A; Quartara L; Maggi CA; Formaggio F; Toniolo C; Mazzucco S; Papini A; Rovero P
J Med Chem; 1999 Feb; 42(3):409-14. PubMed ID: 9986712
[TBL] [Abstract][Full Text] [Related]
17. Structural modification of the highly potent peptide bradykinin B1 receptor antagonist B9958.
Gera L; Stewart JM; Fortin JP; Morissette G; Marceau F
Int Immunopharmacol; 2008 Feb; 8(2):289-92. PubMed ID: 18182242
[TBL] [Abstract][Full Text] [Related]
18. DesArg9-D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin (desArg10-[Hoe140]) is a potent bradykinin B1 receptor antagonist.
Wirth K; Breipohl G; Stechl J; Knolle J; Henke S; Schölkens B
Eur J Pharmacol; 1991 Nov; 205(2):217-8. PubMed ID: 1667388
[TBL] [Abstract][Full Text] [Related]
19. Non-competitive pharmacological antagonism at the rabbit B(1) receptor.
Larrivée JF; Gera L; Houle S; Bouthillier J; Bachvarov DR; Stewart JM; Marceau F
Br J Pharmacol; 2000 Nov; 131(5):885-92. PubMed ID: 11053207
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of potent bradykinin agonists containing a benzothiazepine moiety.
Amblard M; Daffix I; Bedos P; Bergé G; Pruneau D; Paquet JL; Luccarini JM; Bélichard P; Dodey P; Martinez J
J Med Chem; 1999 Oct; 42(20):4185-92. PubMed ID: 10514288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
